Haloperidol Tablets Rx
Generic Name and Formulations:
Haloperidol 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg; scored tabs.
Various generic manufacturers
Indications for Haloperidol Tablets:
Psychosis. Tourette's disorder. For severe behavior disorders or as a short-term treatment for hyperactivity in children who are refractory to psychotherapy or other medications.
Individualize. Initially: Moderate symptoms: 0.5mg–2mg 2–3 times daily. Severe, chronic, or resistant symptoms: 3mg–5mg 2–3 times daily. Debilitated: 0.5mg–2mg 2–3 times daily. Max: 100mg/day.
<3yrs: not recommended. Total dose may be divided, to be given 2–3 times daily. ≥3yrs: initially 0.5mg daily, may increase at increments of 0.5mg at 5–7 day intervals. Psychosis: 0.05mg/kg/day–0.15mg/kg/day. Nonpsychotic behavior and Tourette's: 0.05mg/kg/day–0.075mg/kg/day. Max 6mg/day.
Initially 0.5mg–2mg 2–3 times daily.
Severe CNS depression. Coma. Parkinsonism.
Increased mortality in elderly patients with dementia-related psychosis.
Elderly with dementia-related psychosis (not approved use): increased risk of death. Risk of QT prolongation: electrolyte disturbances (eg, hypokalemia, hypomagnesemia), underlying cardiac abnormalities, hypothyroidism, familial long QT-syndrome, concomitant drugs known to prolong the QT interval. Seizures. Thyrotoxicosis. Pre-existing low WBCs or history of leukopenia/neutropenia; monitor CBCs during 1st few months of treatment; discontinue if WBCs decline. Severe cardiovascular disorders. Mania. Avoid abrupt cessation. Debilitated. Neonates: risk of extrapyramidal and/or withdrawal symptoms post delivery (due to exposure during 3rd-trimester pregnancy). Pregnancy. Nursing mothers: not recommended.
CNS depression potentiated with alcohol, other CNS depressants. Possible neurotoxicity with lithium: monitor, discontinue if occurs. Caution with drugs that prolong the QT interval (eg, ketoconazole, paroxetine). May be potentiated by CYP3A4 inhibitors/substrates or CYP2D6 enzymes (eg, itraconazole, nefazodone, buspirone, venlafaxine, alprazolam, fluvoxamine, quinidine, fluoxetine, sertraline, chlorpromazine, promethazine. May be antagonized by CYP3A4 inducers (eg, rifampin, carbamazepine); monitor and adjust doses. May increase intraocular pressure with anticholinergics. Monitor anticoagulants.
Tardive dyskinesia, extrapyramidal symptoms, CNS effects, GI upset, cardiovascular effects, bronchopneumonia, neuroleptic malignant syndrome.
Formerly known under the brand name Haldol.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC